Podcasts about neurodegenerative disorders

Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.

About the Guest(s): Dr. Laura Standridge: Dr. Laura Standridge is a prominent functional chiropractor known for her expertise in pediatric neurological development and genetic disorders. She is board certified in neurofeedback and specializes in approaches that focus on neurodevelopmental assessments, particularly concerning mitochondrial function and primitive reflexes. Dr. Standridge has gained attention for her work with rare neurodegenerative disorders, particularly BPAN, following her son's diagnosis with the disease. Her professional journey is marked by a dedication to understanding and improving neurological health through innovative methods in functional and integrative healthcare. Episode Summary: In this enlightening episode of Functional Health Radio, Dr. Kristin Hieshetter delves deep into the pressing health crises in America, revealing that the country's life expectancy has not only plateaued but declined for both men and women. Despite the high per capita healthcare expenditure, conditions like heart disease and cancer remain prevalent, and children are increasingly diagnosed with chronic diseases. The discussion transitions into a heartfelt narrative with Dr. Laura Standridge, a functional chiropractor passionately occupied with her son Laird's rare neurodegenerative disease known as BPAN (Beta-propeller Protein-Associated Neurodegeneration). BPAN, characterized by iron accumulation in the brain, is a daunting diagnosis for any family, but Dr. Standridge shares her proactive approach to defy the medical script of decline. Employing advanced genetic testing and leveraging her deep understanding of functional health principles, Dr. Standridge explores comprehensive interventions that have led to remarkable outcomes for Laird. From dietary adjustments to specialized neurodevelopmental therapies and state-of-the-art medical interventions, Dr. Standridge's narrative underscores a hopeful perspective—not only sharing insights about BPAN but also reflecting innovative applications of functional health practices. This episode highlights how a blend of cutting-edge science and compassionate care can write new chapters in health and wellness narratives. Key Takeaways: BPAN Disease Insight: BPAN is a rare neurodegenerative disorder that causes abnormal iron accumulation in the brain, significantly impairing mitochondrial function and autophagy. Unique Case of Laird: Laird defies the typical BPAN trajectory through a tailored combination of nutritional strategies, functional therapies, and mitochondrial enhancement techniques. Importance of Nutrition: Laird's diet, free of gluten and inflammatory foods, supports brain health by preventing autoimmune responses that can exacerbate neurological damage. Integrative Approaches: Utilization of genetic testing and innovative therapies, like low-level laser therapy, provides neuroprotective benefits and enhances Laird's quality of life. Collaborative Healthcare: Dr. Standridge exemplifies the power of interdisciplinary collaboration, uniting various specialists to support a functional health-driven roadmap for Laird. Notable Quotes: "We are walking around in the most amazing, intelligent, responsive, adapting and aware system in the world, the human. Let's bring it to its fullest potential." - Dr. Kristin Hieshetter "It doesn't matter what the label is…I'm much more interested in how you are functioning and not what somebody from the outside might call you." - Dr. Laura Standridge "We waited and we waited and we waited some more and finally received this diagnosis." - Dr. Laura Standridge "The brain is built on the postural system…and so there is this amazing order of neurological development whether you have a genetic difference or not." - Dr. Laura Standridge "Together, we'll be the change that we wish to see in the world." - Dr. Kristin Hieshetter Resources: Learn more about BPAN and related genetic testing at the CDC Vital Statistics Report: www.cdc.gov For insights into functional chiropractic care and Dr. Laura Standridge's approaches, visit Functional Health Mastery Stay informed with the World Economic Forum's health expenditure data: www.weforum.org Functional Health Mastery Group Listen to the full episode to dive deeper into the revolutionary approaches that Dr. Laura Standridge and Dr. Kristin Hieshetter share in tackling BPAN, and stay tuned for more inspiring stories and informative discussions on Functional Health Radio.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.Information physicians receive from the test, and when they should consider ordering it for their patients. Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN. 

Guest Michael Greicius is an authority on Alzheimer's disease. He makes the case that while effective treatments have remained elusive, there are high hopes for new approaches that target tau proteins in the brain associated with the disease. In the meantime, to reduce Alzheimer's risk stay active, eat well, and manage circulatory risks, but skip genetic testing for now until better treatments emerge, Greicius tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile:  Michael GreiciusConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michael Greicius, a professor of neurology and neurological sciences at Stanford University.(00:02:12) Understanding Alzheimer's DiseaseThe roles of amyloid and tau proteins in Alzheimer's disease.(00:04:53) Challenges in Developing TreatmentsThe multiple hurdles in creating Alzheimer's therapies.(00:09:07) Current Alzheimer's DrugsThe controversies and limitations of recently approved drugs.(00:10:23) Amyloid Plaques and Their ImpactWhy removing amyloid plaques hasn't improved patient outcomes.(00:14:29) Problems with Alzheimer's TrialsThe disconnect between amyloid removal and patient outcomes.(00:18:03) Functional Unblinding and Trial BiasHow functional unblinding affects trial results and drug evaluations.(00:23:51) The Potential of Targeting TauNew breakthroughs in targeting tau protein for Alzheimer's.(00:26:35) The Future of PreventionPotential preemptive treatments for Alzheimer's and their administration.(00:29:19) Lifestyle and Risk ReductionRecommendations for reducing risk of Alzheimer's disease.(00:31:43) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

David Perlmutter, MD, FACN, ABIHM, joins Integrative Practitioner Content Specialist Avery St. Onge to discuss new research on the fundamental role of brain microglial cells in the development of neurodegenerative disorders and how they could be targeted for new treatments. This episode is brought to you by the Integrative Healthcare Symposium. Register for the Symposium and receive 15% off with promo code IP2025PODCAST: https://xpressreg.net/register/ihsy0225/landing.php?sc=IP2025PODCAST Learn more about the event by visiting the Symposium website: www.ihsymposium.com Contact the Integrative Healthcare Symposium team: info@ihsymposium.com Find us at integrativepractitioner.com or e-mail us at IPEditor@divcom.com. Theme music: "Upbeat Party" by Scott Holmes via freemusicarchive.org, "Carefree" by Kevin Mcleod via incompetech.com, and “Relaxing Light Background” by AudioCoffee.

In this episode of the Crazy Wisdom Podcast, host Stewart Alsop welcomes Jonathan Dickinson, a specialist in Ibogaine treatment and co-founder/CEO of Ambio Life Sciences and Teregnosis. They discuss the history and therapeutic uses of Iboga and Ibogaine, focusing on its effects in treating heroin addiction, traumatic brain injury, and chronic pain. Jonathan also shares insights into the cultural origins of Iboga, its use in traditional Bwiti ceremonies, and how modern approaches, particularly his work with veterans, expand its applications. More information about Jonathan's work can be found at Ambio Life.Check out this GPT we trained on the conversation!Timestamps00:00 Introduction to the Crazy Wisdom Podcast00:21 Understanding Ibogaine and Its Uses02:00 Ibogaine's Impact on Veterans and Brain Injuries03:57 Psycho-Spiritual and Medical Benefits of Ibogaine07:12 Scientific Studies and Misconceptions18:50 Legalization and Research Challenges25:05 Ibogaine Sourcing and Sustainability31:43 Ibogaine Smuggling and Export Practices32:10 Pharmaceutical Grade Iboga Extract33:36 Challenges of Growing Iboga33:53 Traditional Growth Methods and Cultural Attitudes37:04 Global Cultivation Efforts38:05 Access and Benefit Sharing Agreements38:54 Traditional Knowledge and Bwiti Culture39:40 Historical Context of Iboga Use40:44 Bantu and Pygmy Cultural Exchange42:31 Bwiti Rituals and Practices46:23 Learning from Traditional Practices48:19 Western and Traditional Knowledge Integration55:58 Future of Iboga and Ibogaine59:22 Connecting with AmbioKey InsightsIboga and Ibogaine as Addiction Treatments: Ibogaine is primarily known for its effectiveness in treating heroin addiction. It interrupts the addiction cycle through a powerful psychoactive experience lasting 12-24 hours, which helps individuals detox from drugs like heroin and opioids. After the session, many report being free of withdrawal symptoms and cravings for months, providing a unique pathway out of addiction.Use in Treating Traumatic Brain Injuries (TBI): Jonathan has worked extensively with veterans, especially Navy SEALs, using Ibogaine to address TBIs. These injuries, often from combat-related concussive forces, lead to symptoms that mirror PTSD. Ibogaine appears to regenerate brain function, as seen in a study conducted with Stanford University, where veterans exhibited significant brain activity improvement following treatment.Cultural Roots in Bwiti and African Traditions: Iboga has deep cultural significance in Gabon, particularly in Bwiti spiritual practices, which have been influenced by both indigenous Pygmy traditions and Bantu peoples. Bwiti uses Iboga in ceremonies for psycho-spiritual exploration, healing, and connection to ancestors, a tradition that has persisted for centuries and possibly millennia.Misunderstandings About Noribogaine: Many believe that noribogaine, a metabolite of Ibogaine, remains in the body for up to eight months, contributing to long-lasting effects. However, Jonathan clarifies that noribogaine remains in the system for only a few days or a week. The extended feeling of ease or afterglow people experience may be due to neurotrophic factors like GDNF, which stimulate brain healing and regeneration over time.Emerging Scientific Understanding of Ibogaine: Research into Ibogaine's mechanisms is still developing. It acts on many receptors in the brain, including the Sigma 2 receptor, which has been linked to pain relief and neuroprotective effects. There's also growing interest in its potential role in intracellular processes and energy metabolism, where it appears to improve cellular efficiency, possibly explaining its long-term regenerative effects on brain function.Decentralized Knowledge and Treatment Communities: Unlike tightly regulated pharmaceutical models, Ibogaine treatment has grown in a decentralized, community-driven way, with providers sharing their experiences and knowledge. This echoes the traditions of Bwiti and emphasizes the importance of communal support around Ibogaine therapy, where the intensity of the experience requires a supportive environment and a collective sharing of insights.Sustainability and Ethical Sourcing of Iboga: Jonathan is actively involved in ensuring the sustainable and ethical sourcing of Iboga through his company, Teregnosis. Working with Gabonese communities, Teregnosis follows the Nagoya Protocol to ensure that the benefits of Iboga's growing global interest are shared with the traditional communities that have long relied on this plant, protecting both the ecosystem and cultural heritage.

I get a little giddy when I come across a novel mitochondrial-boosting strategy; particularly, when its mechanisms of how it impacts the mitochondria aren't redundant with other powerful modalities, such as red light therapy, methylene blue and C60. Of course, it must also be safe, efficacious and backed by research for it to even be a consideration. Well, ladies and gentleman, the amino acid taurine fits that bill to a tee!If you're like me, taurine may have a knee-jerk negative connotation due to its association with energy drinks. But if that's the case, I politely ask you to table that association as we head into this episode. The more I have learned about this mysteriously overlooked amino acid, and its science-backed efficacy for improving mitochondrial function in a myriad of way, the more I have gotten excited to report this information to you. Taurine is the real deal!In this episode, I will be providing "knowledge snacks" from a textbook I recently read, "Taurine and the Mitochondrion: Applications in the Pharmacotherapy of Human Diseases." The chapters and information covered in part one include the synthesis, dietary sources, and mechanisms of action of taurine; taurine and the mitochondrion; and applications of taurine in the central nervous system disorders linked with mitochondrial impairment. Subsequent parts of this series will cover other diseases and body systems impacted by mitochondrial dysfunction and how taurine may play a pivotal role in mitigating, preventing and/or reversing aforementioned conditions. If you found the information in today's episode particularly interesting and/or compelling, please share it with a family member, friend, colleague and/or anyone that you think could benefit and be illuminated by this knowledge. Sharing is caring :)As always, light up your health! - Book referenced in episode: Taurine and the Mitochondrion: Applications in the Pharmacotherapy of Human Diseases - Key Points: [00:00] - Introduction: Welcome to the Red Light Report. [00:13] - Mitochondrial Triad and Happy Autumn Equinox. [00:50] - Announcements: Recap of oral health benefits of red and blue light, introduction of Illume toothbrush. [01:22] - Illume Toothbrush: Pre-orders fulfilled, benefits of red and blue frequencies for oral health. [02:12] - Upcoming: Biological dentists' feedback on Illume toothbrush. [02:33] - Today's Topic: Taurine and its role in health. [03:05] - Misconceptions about Taurine: Association with energy drinks. [04:09] - Taurine's Impact on Mitochondria: Bioenergetic benefits and physiological function. [05:11] - Mitochondrial Function: Root cause of chronic diseases and health optimization. [06:15] - Taurine and Mitochondria: Chapter overview of taurine's impact on various systems. [08:21] - Taurine's Mechanisms: Redundancy across different organ systems. [09:45] - Taurine Book Introduction: Overview and authors. [11:07] - Taurine Benefits: Impact on various organs and its role in pharmacological processes. [12:30] - Taurine Synthesis and Dietary Sources: Differences between species and taurine-rich foods. [13:51] - CSD Activity and Taurine Deficiency: Synthesis in humans and food sources like oysters. [15:04] - Taurine in Energy-Intensive Organs: Concentrations in the brain, heart, and muscles. [16:43] - Mitochondrial Dysfunction: How taurine impacts high-energy organs. [18:27] - Taurine's Role in Calcium Homeostasis: Buffering overload and stabilizing mitochondrial function. [19:59] - Chapter 2: Taurine's cytoprotective properties in mitochondria. [21:18] - Taurine & Mitochondrial Function [22:10] - Clarifying Cytochrome C vs Cytochrome C Oxidase [23:39] - Taurine & Mitochondrial ATP Production [25:53] - Taurine's Role in Cellular Calcium Regulation [27:33] - Applications of Taurine in the Central Nervous System [28:42] - Excitotoxicity & Neurodegenerative Diseases [29:57] - Questioning Nitric Oxide Benefits [32:24] - Taurine & Stroke Protection [35:11] - Taurine & Traumatic Brain Injury (TBI) [39:23] - Taurine & Seizures/Epilepsy [41:15] - Taurine & Neurodegenerative Disorders [42:02] - Introduction to Taurine and Alzheimer's Disease [42:16] - Taurine's Role in Preventing Amyloid Beta Aggregation [43:04] - Mitochondrial Impairment in Parkinson's Disease [44:07] - Taurine's Impact on Dopaminergic Neurons [45:32] - Taurine's Potential Role in Huntington's Disease [46:16] - Taurine's Mitochondrial Benefits in Huntington's Disease Models [47:18] - Excitotoxicity and NMDA Receptor Hyperactivation in Huntington's Disease [48:30] - Taurine's Effect on GABA Levels in Huntington's Disease [50:14] - BioLite Product Announcement: BioBlue Capsules [51:12] - Advantages of BioBlue Capsule Version [52:05] - Capsule Ingredients: Methylene Blue and Taurine [53:18] - Dosage Details for BioBlue Capsules [57:03] - Benefits of Methylene Blue and Taurine for Mitochondria [58:34 - Coupon Code and Pre-Order Information [59:46] - Conclusion and Teaser for Part Two on Taurine -   Announcing BioLight's most innovative product: BioLight Illume! BioLight's patent-pending technology brings the power of red and blue LEDs into a sonic toothbrush. Now your mouth can receive the many benefits of red and blue light!   For the rest of September, order your Illume toothbrush and get a 15% discount! Simply use discount code "illume15"   To light up your smile, click here - Dr. Mike's #1 recommendations: Water products: Water & Wellness Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light-blocking glasses: Ra Optics - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

In this episode of The Root Cause Medicine Podcast, we dive into Alzheimer's, dementia, and brain health with Max Lugavere and Chris Newhard. You'll hear us discuss: 1. The inspiration behind Little Empty Boxes 2. Myths and truths about dementia 3. Why by 2050 150 million people will have Alzheimer's 4. What really causes brain damage 5. Why there's no one-size-fits-all diet for brain health 6. How building muscle increases longevity and brain health Max is a health and science journalist, filmmaker, and bestselling author. He wrote the Genius trilogy, which includes Genius Foods, Genius Kitchen, and The Genius Life. Max also hosts The Genius Life podcast, a leading health and wellness show in the US, and has appeared on The Joe Rogan Experience, The Rachael Ray Show, The Today Show, and PBS's Brief but Spectacular. Chris is a filmmaker from Philadelphia who has built his career as a cinematographer and director. In 2017, he founded Booklight, a production company focused on documentary and narrative work. His diverse experience includes directing music videos for artists like Sia, Maroon 5, and Jessie J. Chris and Max recently worked together on the Little Empty Boxes documentary, which highlights Max's efforts to slow his mother's (Kathy Lugavare) dementia. The film offers an honest look at Kathy's journey and the challenges Max faces as he does everything he can to support her. Order tests through Rupa Health, the BEST place to order functional medicine lab tests from 30+ labs - https://www.rupahealth.com/reference-guide

The introduction is done by Dr. Steven Flanagan, Chairperson of the Department of Rehabilitation at NYU Langone Health. His remarks ended at the 2 minute: 24 second mark. Dr. Darryl Kaelin is the Endowed Chair of Stroke and Brain Injury Rehabilitation at the University of Louisville. In this Grand Rounds session, he speaks about Traumatic Brain Injury and its Association with Neurodegenerative Disorders. Part 1 Dr. Kaelin described the interesting relationship between the University of Louisville Frazier Rehabilitation Institute and NYU Rusk in New York. The Institute has its origins at NYU. His presentation had a focus on cellular level and pathophysiology that contribute to complications of brain injury, Alzheimer's type dementia, Parkinson's Disease and some similarities that exist. He began a literature review one-year ago on this topic, which has led to today's discussion. It is important to start by talking a little about the pathophysiology TBI and cerebral insults. It can have some correlation to stroke and other insults to the brain and central nervous system. He also talked a little bit about things that we don't think about much as physiatrists –astrocytes and microglia and what their roles are in the brain and in brain trauma. He indicated that astrocytes are the scaffolding or the structure upon which neurons and other cells hold themselves to and create the structure and shape of the brain. Microglial cells help in brain infection and brain inflammation. In a resting, healthy brain they are highly mobile and will undergo morphological changes following a brain trauma. He indicated that synapses between neurons are significantly affected both mechanically and in becoming lost in severe brain injury. He discussed the importance of sleep for patients with a brain injury. Part 2 Repetitive mild brain injuries also can result in the same kinds of findings. So, it is not just moderate to severe, but repetitive mild injuries that increase the risk. Although there may not be a direct causal relationship, certainly having a brain injury, multiple mild brain injuries or a moderate to severe brain injury increases the risk of developing neurodegenerative processes like Alzheimer's and Parkinson's.  He tells his patients that the likelihood of developing a neurodegenerative process may be there, but in each individual it can be different. We don't know specifically what it might mean for you. On average the risk may go up, but it still is very small. He talked about some potential neuro-protective treatments that might exist out there or are in the process of being looked at. He stated that this patient population is heavily heterogeneous, especially in how it presents and responds to trauma. Additionally, patients in the U.S. don't all receive exactly the same treatment after their trauma, which is a confounding variable that results in a very different outcome for each of those kinds of patients. Nutrition is a highly important factor when it comes to recovery and outcomes.  Parenteral nutrition goes a long way in helping their outcomes. It also is important to keep an eye on vitamin and mineral levels.  Zinc is a key supplement for many patients and magnesium can help in recovery. He closed by describing a disorders of consciousness program at his institution called the Emerge Program. A Question &Answer period followed.  

The introduction is done by Dr. Steven Flanagan, Chairperson of the Department of Rehabilitation at NYU Langone Health.  Dr. Darryl Kaelin is the Endowed Chair of Stroke and Brain Injury Rehabilitation at the University of Louisville. In this Grand Rounds session, he speaks about Traumatic Brain Injury and its Association with Neurodegenerative Disorders. Part 1 Dr. Kaelin described the interesting relationship between the University of Louisville Frazier Rehabilitation Institute and NYU Rusk in New York. The Institute has its origins at NYU. His presentation had a focus on cellular level and pathophysiology that contribute to complications of brain injury, Alzheimer's type dementia, Parkinson's Disease and some similarities that exist. He began a literature review one-year ago on this topic, which has led to today's discussion. It is important to start by talking a little about the pathophysiology TBI and cerebral insults. It can have some correlation to stroke and other insults to the brain and central nervous system. He also talked a little bit about things that we don't think about much as physiatrists –astrocytes and microglia and what their roles are in the brain and in brain trauma. He indicated that astrocytes are the scaffolding or the structure upon which neurons and other cells hold themselves to and create the structure and shape of the brain. Microglial cells help in brain infection and brain inflammation. In a resting, healthy brain they are highly mobile and will undergo morphological changes following a brain trauma. He indicated that synapses between neurons are significantly affected both mechanically and in becoming lost in severe brain injury. He discussed the importance of sleep for patients with a brain injury. Part 2 Repetitive mild brain injuries also can result in the same kinds of findings. So, it is not just moderate to severe, but repetitive mild injuries that increase the risk. Although there may not be a direct causal relationship, certainly having a brain injury, multiple mild brain injuries or a moderate to severe brain injury increases the risk of developing neurodegenerative processes like Alzheimer's and Parkinson's.  He tells his patients that the likelihood of developing a neurodegenerative process may be there, but in each individual it can be different. We don't know specifically what it might mean for you. On average the risk may go up, but it still is very small. He talked about some potential neuro-protective treatments that might exist out there or are in the process of being looked at. He stated that this patient population is heavily heterogeneous, especially in how it presents and responds to trauma. Additionally, patients in the U.S. don't all receive exactly the same treatment after their trauma, which is a confounding variable that results in a very different outcome for each of those kinds of patients. Nutrition is a highly important factor when it comes to recovery and outcomes.  Parenteral nutrition goes a long way in helping their outcomes. It also is important to keep an eye on vitamin and mineral levels.  Zinc is a key supplement for many patients and magnesium can help in recovery. He closed by describing a disorders of consciousness program at his institution called the Emerge Program. A Question &Answer period followed

In this episode of The Performance Initiative Podcast, hosts Dr. Grant Cooper and Dr. Zinovy Meyler engage in a comprehensive discussion with Dr. Leroy Hood, a world-renowned scientist and pioneer in personalized, data-driven medicine. They explore the radical overhaul needed in the U.S. healthcare system, emphasizing its focus on disease rather than wellness. Dr. Hood shares his vision for a future where data-driven health allows early detection and prevention of diseases through biomarkers and AI. Key topics include the prevention of neurodegenerative diseases, optimizing aging, the transformative role of AI in healthcare, and the potential economic benefits of reducing chronic diseases. The conversation also addresses the challenges and strategies for integrating participatory healthcare, ensuring data privacy, and the potential societal impacts of extending healthy lifespans. The podcast wraps up with practical advice for maintaining cognitive health and an encouraging vision for the future of medicine.(00:00) Introduction(01:58) Lee Hood's Background and Achievements(03:08) The Vision for Future Medicine(11:16) The Role of AI in Transforming Healthcare(16:38) Challenges and Pushbacks in Data-Driven Health(34:02) The Importance of Participatory Healthcare(47:26) Genetic Risk and Cholesterol Management(48:24) Polygenic Scores and Preventive Measures(50:56) AI and Data Integration in Health(52:29) Digital Twins and Alzheimer's Research(56:43) Data Security and Ethical Concerns(01:02:09) Personalized Medicine and Infectious Diseases(01:07:58) Neurodegenerative Disorders and Multimodal Therapy(01:13:29) Cognitive Training and Brain Health(01:22:00) Future of Personalized Medicine(01:25:38) Conclusion and Final ThoughtsLeroy Hood is a pioneering American biologist and technologist renowned for his significant contributions to biotechnology and genomics. He played a crucial role in the development of the automated DNA sequencer, which revolutionized genomic research and paved the way for the Human Genome Project. Hood's work also encompasses the invention of other groundbreaking technologies, such as the automated protein sequencer and the ink-jet DNA synthesizer. Throughout his career, he has been a strong advocate for interdisciplinary approaches to biology, integrating engineering and computational methods to advance personalized medicine. His achievements have earned him numerous accolades, including the National Medal of Science and election to the National Academy of Sciences.

Dr. Marc Funderlich, Regenerative Cell Therapy Management Corporation (LaserLife Insights, Episode 7) On this episode of LaserLife Insights, hosted by Pete Cousins, Dr. Mark Funderlich shares his extensive experience and insights into regenerative medicine, focusing on the use of stem cells, exosomes, peptides, and laser therapy. As a chiropractor and co-founder of the Regenerative Cell Therapy […]

In neurodegenerative conditions such as Parkinson's disease (PD), patients often do not receive a diagnosis until the hallmark motor symptoms begin to manifest. This can be a decade or more after substantial changes start occurring in the brain. A major goal of the PD research field has been to develop methods for earlier detection and intervention. Over the years, there have been substantial advances in neuroimaging techniques and biological biomarkers that have allowed us to more accurately identify patients with Parkinson's disease, including the recent development of the alpha-synuclein seed amplification assay. In this episode, Dr. John Seibyl discusses his early work on neuroimaging in Parkinson's disease through to the groundbreaking, large-scale clinical trials he is involved with for assessing the impacts of neuroprotective drugs for Parkinson's disease as well as Alzheimer's disease. He also shares his perspectives as a researcher and a patient with Parkinson's disease. John is Chairman of the Board, Co-Founder, and Senior Scientist of the Institute for Neurodegenerative Disorders in New Haven, Connecticut. He is also a board-certified physician in both Psychiatry and Nuclear Medicine, and he is an Adjunct faculty member in Neurology at Yale University School of Medicine.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

In neurodegenerative conditions such as Parkinson's disease (PD), patients often do not receive a diagnosis until the hallmark motor symptoms begin to manifest. This can be a decade or more after substantial changes start occurring in the brain. A major goal of the PD research field has been to develop methods for earlier detection and intervention. Over the years, there have been substantial advances in neuroimaging techniques and biological biomarkers that have allowed us to more accurately identify patients with Parkinson's disease, including the recent development of the alpha-synuclein seed amplification assay. In this episode, Dr. John Seibyl discusses his early work on neuroimaging in Parkinson's disease through to the groundbreaking, large-scale clinical trials he is involved with for assessing the impacts of neuroprotective drugs for Parkinson's disease as well as Alzheimer's disease. He also shares his perspectives as a researcher and a patient with Parkinson's disease. John is Chairman of the Board, Co-Founder, and Senior Scientist of the Institute for Neurodegenerative Disorders in New Haven, Connecticut. He is also a board-certified physician in both Psychiatry and Nuclear Medicine, and he is an Adjunct faculty member in Neurology at Yale University School of Medicine.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Dietary management of major psychiatric disorders Understanding the importance of diet in mental health disorders Reality is that we need to take into consideration fundamental beliefs and facts to assist in the achievement of clarity and step outside of what has been learnt which can be difficult   Host: Dr David Lim | Total Time: 44 mins Guest: Dr Matthew Phillips, Metabolic Neurologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next oneSee omnystudio.com/listener for privacy information.

CranioSacral Therapy -The Missing Piece To Alzheimer's Care Discover a groundbreaking approach to Alzheimer's care in this enlightening talk by Michael Morgan LMT, CSTD. Drawing on his extensive experience in CranioSacral Therapy, Morgan reveals the crucial role of fascia in brain health and offers a promising new perspective on the treatment of Alzheimer's. Dive into fascinating discussions on fascia, stem cells, and practical home therapies designed to improve brain health. #AlzheimersCare #CranioSacralTherapy #brainhealth Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Join us for part 2 of our discussion with neurologist Dr. Erik Ensrud as we continue to discuss neurodegenerative disorders and explore the factors that WE can control that may decrease our risk or modify our course if we are indeed diagnosed. Please, join our community https://members.lastingimpactwellness.com/podcast-newsletter-signup As always, questions, comments & topic suggestions welcome at info@lastingimpactwellness.com Follow us on Instagram & Facebook @lastingimpactwellness Please be sure to subscribe, leave us a review & SHARE this podcast with others! We truly appreciate your support. Original music by EP3 Episode references: Alzheimer's Association Parkinson's Foundation Erickson KI, Raji CA, Lopez OL, Becker JT, Rosano C, Newman AB, Gach HM, Thompson PM, Ho AJ, Kuller LH. Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. Neurology. 2010 Oct 19;75(16):1415-22. https://health.ucdavis.edu/news/headlines/volunteering-in-late-life-may-protect-the-brain-against-cognitive-decline-and-dementia/2023/07#:~:text=(Sacramento)%20Volunteering%20in%20late%20life,International%20Conference%202023%20in%20Amsterdam. Day SM, Gironda SC, Clarke CW, Snipes JA, Nicol NI, Kamran H, Vaughan W, Weiner JL, Macauley SL. Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice. Neurobiol Dis. 2023 Feb;177:105967. Sabia S, Fayosse A, Dumurgier J, van Hees VT, Paquet C, Sommerlad A, Kivimäki M, Dugravot A, Singh-Manoux A. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun. 2021 Apr 20;12(1):2289. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14.

What The Latest Science Says About Preventing Alzheimer's And Dementia Join Michael Morgan LMT CSTD as he hosts an enlightening conversation with renowned expert, Dr. Dale Bredesen, MD. They delve into the latest science behind preventing Alzheimer's and Dementia, exploring intricate facets such as holistic healing, the power of sleep and diet, and breakthroughs in research. Watch as they unravel the complexity of these conditions and offer a beacon of hope for the future. #AlzheimersResearch #DementiaPrevention #HolisticHealing Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Progressive decline in our brains and nervous system, more than other types of disease, truly challenges who we are as individual people. Neurodegenerative disorders such as Alzheimers, Parkinson's, Multiple Sclerosis and others are among the most feared possibilities we face. Join us for a two part discussion with neurologist Dr. Erik Ensrud to learn about the range of these diseases that affect millions of people. But more than a review, the message is that now, more than ever, we can do something about changing our risk of ever getting these diseases or the rate of progression if we do. As always, questions, comments & topic suggestions welcome at info@lastingimpactwellness.com Follow us on Instagram & Facebook @lastingimpactwellness Please be sure to subscribe, leave us a review & SHARE this podcast with others! We truly appreciate your support. Original music by EP3 Episode references: Alzheimer's Association Parkinson's Foundation Erickson KI, Raji CA, Lopez OL, Becker JT, Rosano C, Newman AB, Gach HM, Thompson PM, Ho AJ, Kuller LH. Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. Neurology. 2010 Oct 19;75(16):1415-22. https://health.ucdavis.edu/news/headlines/volunteering-in-late-life-may-protect-the-brain-against-cognitive-decline-and-dementia/2023/07#:~:text=(Sacramento)%20Volunteering%20in%20late%20life,International%20Conference%202023%20in%20Amsterdam. Day SM, Gironda SC, Clarke CW, Snipes JA, Nicol NI, Kamran H, Vaughan W, Weiner JL, Macauley SL. Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice. Neurobiol Dis. 2023 Feb;177:105967. Sabia S, Fayosse A, Dumurgier J, van Hees VT, Paquet C, Sommerlad A, Kivimäki M, Dugravot A, Singh-Manoux A. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun. 2021 Apr 20;12(1):2289. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14.

Dementia Researcher hosted a YouTube / Twitter Livestream on the 23rd June 2023 exploring Motor Neurone Disease (MND) and the remarkable advancements in research, in partnership with MND Scotland. We enjoyed the session so much, that we decided to release it as a bonus 'extra' podcast - so please ignore any references to links on the screen. Listen to learn more about the disease, the latest advancements in MND research, and specifically about the groundbreaking MND Smart Trial. This unique trial has garnered attention for its innovative approach and has shown promising potential in accelerating the discovery of effective treatments for MND. Furthermore, the event will delve into the impact of new investments in MND research, exploring how these resources are driving progress and propelling the quest for a cure. Resources mentioned during the recording: MND-SMART Website - https://mnd-smart.org/ MND Scotland Website - https://mndscotland.org.uk/ Jane Blog - https://www.dementiaresearcher.nihr.ac.uk/guest-blog-uk-motor-neuron-disease-research-institute/ *We can now confirm that the MND-SMART Study does sit on the NIHR Portfolio CPMS ID 44601 for any interested NHS sites. Adam Smith hosted the session, and was joined by: Dr Jane Haley, representing MND Scotland, brings her extensive expertise and compassionate approach to the discussion. As the Director of Research at MND Scotland, Dr. Haley has been instrumental in bringing the thoughts and priorities of people affected by MND into research and driving forward research initiatives and partnerships. Suvankar Pal is a Professor of Neurodegenerative Disorders and Clinical Trials at the University of Edinburgh. He is co-lead investigator of the innovative MND-SMART trial, the largest ever Phase 3 trial for people living with MND in the UK. Stevie Morris was diagnosed with MND in February 2021. He will bring insights to life, sharing the realities of living with the disease, highlighting the challenges faced by individuals living with MND and the importance of research in improving their quality of life. Don't miss this extraordinary opportunity to expand your knowledge, engage with leading experts, and gain insights into the pioneering MND-SMART Trial. Join us on the livestream as we embark on a journey to accelerate discovery and make a difference in the lives of those affected by MND.

CNS analysts discuss neurodegenerative disorders - Parkinson's and Alzheimer's disease Alzheimer's Disease Forecast https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/alzheimers-disease/forecast/article155358.ece Alzheimer's Disease Analysis Report https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/alzheimers-disease/disease-analysis/article209751.ece Parkinson's Disease Analysis Report https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/parkinsons-disease/disease-analysis/article218480.ece Parkinson's Disease Forecast https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/neurology/parkinsons-disease/forecast/article138452.ece Other platforms Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/ Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67

Recent advancements in research has led to the development of effective therapeutics to combat neurodegenerative diseases, giving patients a renewed sense of hope there will ultimately be a more effective treatment.CEO Lisa Deschamps and her team at AviadoBio are among those conducting research in the space, but they're doing things a little differently. They've been given a unique drug designation by the FDA to develop a treatment for frontotemporal dementia (FTD), a crippling neurodegenerative disorder that affects neuron production in people under 65. It may be a “bold and courageous” undertaking, but the benefits could affect future generations to come.Join us as we take a look at the motivation behind the work AviadoBio is doing, what makes their therapy unique, and Lisa's vision for their future.Show Notes  AviadoBio  S4, E01: Project ALS: Fueled by Love  S3, E01: A Synergistic Approach to Treating Huntington's Disease  Charles River | Neuroscience  Charles River | Gene Therapy for Neurological Disorders  Charles River| GEne Therapy Services  

An experimental Alzheimer's drug really may be 'historic,' and some stunning data on what COVID does to people's brains. Also, is coffee good (or bad) for your heart?

Lisa Deschamps' story is one of determination and fortitude. She got her start in the life sciences where it begins and ends for many— "carrying the bag" in big pharma sales—then proceeded to crush the odds on her way to the C-suite at Novartis. Today, she's CEO at AviadoBio, a disruptive gene therapy startup prepping an intra-thalamic Frontotemporal Dementia candidate for the clinic with a heavy Series A in its hip pocket. On this episode of the Business of Biotech we get to know Lisa, her company and its therapeutic approach, her advocacy for genetic testing, and how she's applying her determination and fortitude to enabling more women to become life science leaders. 

My guest today is Bree Gordon who specializes in working with seniors with Neurodegenerative Disorders, oncology patients and trauma survivors of all ages. She is an accomplished public speaker on topics of music therapy, intergenerational connection, trauma-informed care and business coaching. Bree is also the owner and Director for Creative Arts Therapies of the Palm Beaches and hosts the podcasts The Mindful Mentor. In addition to her clinical work as a music therapist, Bree has been an active volunteer and advocate for senior rights for the past 15 years, including advocating at the Florida state capitol. She has spoken at conferences for the Alzheimer's Association, Alzheimer's Foundation of America, Florida Adult Day Services Association and several national and regional American Music Therapy Association events. You can follow her work on her website at https://www.mindfulbree.com/, Instagram @mindfulmentorbree and on Facebook @TheMindfulMentor.

Dr. Mafee is dual board certified in Neurology and Integrative Medicine.  As such, she is passionate about using functional and integrative philosophies to prevent & reverse a host of chronic conditions.  Dr. Mafee is particularly focused on helping patients work through neurodegenerative disorders.   Dr. Mafee joined the Case Integrative Health team in March 2020. ​ Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don't reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson's, Alzheimer's, and Huntington's disease. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias). Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer's representing approximately 60-70% of dementia cases. (Credits: JPND)  

On this episode we take a look at the role induced Pluripotent Stem Cells (iPSCs) are playing in drug discovery and development for neurodegenerative diseases. Our host Oleksandr sat down with Professor Evangelos Kiskinis, who is leading his own research group at the Northwestern University in Chicago. Evangelos and his team are leading the way on the development of novel cell-based models for ALS, epilepsy and other types of neurological conditions.Check out this episode to learn more about:◦ Evangelos's career story and what got him excited in stem cell research◦ Challenges in modeling neurodegenerative diseases in a dish◦ iPSC based models for inherited vs sporadic diseases◦ Transitioning promising in vitro discoveries into clinical trials◦ iPSC based cell replacement therapies for Parkinsons and Alzheimers disease◦ The future of iPSC based models in drug discovery◦ Evangelos's advice to young scientists pursuing academic career◦ Get in touch with Evangelos:◦ LinkedIn: Evangelos Kiskinis ◦ Web: http://evangeloskiskinislab.org/index.htmlMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Professor Javier Fernández-Ruiz is Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine at the Complutense University of Madrid. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. Professor Fernandez is also a member of the Editorial Board in the British Journal of Pharmacology. He has authored several papers outlining the therapeutic potential of cannabinoids in degenerative disorders including:Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical ApplicationsEndocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and OthersCannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomesProspects for cannabinoid therapies in basal ganglia disordersAs Professor Fernandez mentioned in the podcast, he is happy to be contacted by anyone interested in finding out more about his area of research and can be emailed on jjfr@med.ucm.es. (Please remember he is not a medical doctor). Support the show (https://www.paypal.com/paypalme/marybiles71)

MS3 Tiana DiMasi is back to host an episode reviewing some of the most common neurodegenerative disorders, including Parkinson's, Alzheimer's, Huntington's, frontotemporal dementia, Lewy body dementia, vascular dementia, and more. We'll also cover some common medical conditions that can masquerade as neurodegenerative disorders. Get excited for a thorough review!

Part 2 of the last episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Part 2 of the last episode.

» Define Neurodegenerative Disorders » Explore the bidirectional interaction of mood and NDs » Review the functions of serotonin and dopamine in mood and neurodegenerative disorders » Describe the symptoms of NDs » Explore Primary, Secondary and Tertiary prevention of NDs Learn more about your ad choices. Visit megaphone.fm/adchoices

» Define Neurodegenerative Disorders » Explore the bidirectional interaction of mood and NDs » Review the functions of serotonin and dopamine in mood and neurodegenerative disorders » Describe the symptoms of NDs » Explore Primary, Secondary and Tertiary prevention of NDs

In this episode, Dr. Randel Swanson, Physiatrist from the University of Pennsylvania, will explain why traumatic brain injury (TBI) survivors are at an increased risk of developing age related cognitive decline and what can be done to approach risk mitigation to deal with this issue. In addition, Dr. Swanson will provide evidence based research to find out more about how to maximize brain health. Please see below for resources: Dietary Guidelines, 2020-2025: https://health.gov/our-work/food-nutrition/current-dietary-guidelines Physical Activity Guidelines: https://health.gov/our-work/physical-activity/current-guidelines Dr. Swanson is a board-certified Physiatrist, with sub-specialty certification in Brain Injury Medicine. Dr. Swanson's clinical practice centers on the Neurological Rehabilitation of patients with Acquired Brain Injury, both at Penn and within the VA's Polytrauma/TBI System of Care. His goal is to assist patients in achieving optimal return of neurological function following all forms of Brain Injury (including Traumatic Brain Injury (TBI), Anoxic Brain Injury, Cerebral Vascular Accidents (Stroke), Brain Tumors, Movement Disorders and Neurodegenerative Disorders) through a combination of clinical practice and scientific research. Dr. Swanson also runs a research laboratory within the VA's Center for Neurotrauma, Neurodegeneration and Restoration (CNNR), and is a member of Penn's Center for Brain Injury and Repair (CBIR).

Hosts: Anna Brooks Allen and Audrey Best Guest: Dr. Guy Caldwell Dr. Caldwell studies neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, and ALS by observing the model organism C. elegans in his lab called the Work Shack. He is a University Distinguished Research Professor at the University of Alabama.The researchers in the Caldwell lab investigate the molecular mechanisms of organismal regulation and metabolic response to protein stressors implicated in human neurological diseases including Parkinson's, Alzheimer's, and related disorders. The focus is on discovery of gene targets for therapeutic development and drug discovery, as well as environmental contributors to neurodegeneration using the nematode model system. For more information about The Caldwell Lab, check out his website: http://wormshack.ua.edu

In this latest episode of the Neurology section, Dr Bharadwaj Chada explores two of the most common neurodegenerative disorders: Alzheimer's and Parkinson's disease.

Tyler chats with Barbara Barclay of RightEye to learn how eye-tracking technologies are being used to identify and assist in a wide variety of movement disorders, including Traumatic Brain Injuries and neurodegenerative disorders like Parkinson's. Barbara relates how eye tracking is being used at 10 Veteran Administration hospitals in clinical trials and some of the dramatic examples of how treating eye tracking issues have helped veterans, athletes, and many others. Institutions that have used RightEye's database include the U.S. Department of Veterans Affairs, U.S. Department of Defense, Richmond Veteran Affairs Medical Center, University of Florida, Emory University, Duke University, and many others.  Support the show (https://www.paypal.com/donate?hosted_button_id=DPPU22JG5EM6Y)

Dr. Rohit Dhall, MD, Associate Professor of Neurology and Director of Neurodegenerative Disorders at the University of Arkansas discusses essential tremors (ET) and a new wrist-worn bioelectronic device, called the Cala Trio™ that is the only non-invasive, non-drug therapy that goes directly to the source of tremor by delivering advanced targeted therapy that safely and effectively reduces hand tremors. In a recent breakthrough study presented at the International Congress of Parkinson’s and Movement Disorder Congress (MDS), it was shown to be safe and effective in a real-world setting. He is joined by Beverly who has been using Cala Trio™ for her condition.

Dr. Jason Crowell discusses genetic testing in the diagnostic evaluation and management of patients with common neurodegenerative disorders, one of the many programs at the upcoming AAN Fall Conference. The AAN Fall Conference will be held on November 6-7 (virtually). Click here for more information: https://www.aan.com/conferences-community/regional-conferences/fall-conference/

Currently, there are about 50 million people with Alzheimer's, 50 million people with Dementia and 10 million people with Parkinson's disease. Unfortunately, these disorders are difficult to treat, and many remain incurable. The existing treatments for Alzheimer's (AD) have limited effectiveness and focus primarily on relieving symptoms rather than slowing the underlying disease. There is a major demand for new treatments, but despite significant efforts, few drug candidates have shown promising results. On this Disruption Everywhere podcast, we will be discussing how a protein called CDK5, has a significant influence on brain function, a key target for treating multiple neurodegenerative diseases with Dr. Kent Werner, Founder and CEO of Cogentis Therapeutics. Listen in on how Cogentis groundbreaking research discovers and develops first-in-class therapeutics that prevent neurodegeneration and restore brain function to benefit the lives of those patients and their families. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/disruptioneverywhere/support

Dr. Elias Druckman DC has a strong background in functional neurology and functional medicine. He has found a passion for helping the elderly with a non-pharmaceutical approach to health and aging. www.neurologicwellnessinstitute.com

In this episode of The Functional Medicine Radio Show, Dr. Carri's special guest Dr. Greg Eckel explains his FAN-C Approach to Parkinson's Disease and other neurodegenerative disorders. The combination of Naturopathic and Chinese Medicine (acupuncture and botanical medicine) has provided Dr. Eckel with a variety of tools to treat both acute and chronic illness while […] The post Neurodegenerative Disorders with Dr. Greg Eckel appeared first on The Functional Medicine Radio Show With Dr. Carri.

MS News Today's columnist, Jenn Powell, discusses EyeStat's promise of early detection in the onset of neurodegenerative disorders such as Multiple Sclerosis. Are you interested in learning more about Multiple Sclerosis? If so, please visit https://multiplesclerosisnewstoday.com/

In this episode, Bree talks about her journey to becoming a music therapist, how she developed knowledge and a program to benefit survivors of school shootings, and how she is constantly expanding her own work as well as her companies. Take a listen to be inspired and hear Bree's passions! Bree earned her Bachelor’s degree in Music Therapy with a concentration in voice from Nazareth College in Rochester, NY.  After completing a 6-month internship at Hospice of Palm Beach County, Bree earned her board-certification.  She also received training and certification from the Academy of Neurologic Music Therapy at Colorado State University.  Clinically, Bree specializes in working with seniors with Neurodegenerative Disorders and trauma survivors of all ages.  Bree is an accomplished public speaker on topics of music therapy, intergenerational connection, trauma-informed care and business coaching. Creative Arts Therapies of the Palm Beaches Website. Also, find them on Facebook! NPR Interview with Parkland Survivors, "To Cope With Shooting, Parkland Students Use Art, Music Therapy" Parkland Town Hall from CNN The Body Keeps The Score by Bessel Van Der Kolk Holistic Psychologist Tara Brach  Stay Tuned for Bree's Personal Website for Public Speaking! Follow us on Instagram! Looking for more creative content? Sign up for our newsletter and get a free creativity guide! Join the Creative Therapy Umbrella Hub Facebook group to further discuss, collaborate, and create with your fellow creative arts therapy community! Have feedback? Fill out our anonymous survey to let us know your thoughts, concerns, questions, suggestions, and feedback. For us to serve you better, we need to hear YOUR voice!  

In this episode, Bree talks about her journey to becoming a music therapist, how she developed knowledge and a program to benefit survivors of school shootings, and how she is constantly expanding her own work as well as her companies. Take a listen to be inspired and hear Bree's passions!Bree earned her Bachelor’s degree in Music Therapy with a concentration in voice from Nazareth College in Rochester, NY. After completing a 6-month internship at Hospice of Palm Beach County, Bree earned her board-certification. She also received training and certification from the Academy of Neurologic Music Therapy at Colorado State University. Clinically, Bree specializes in working with seniors with Neurodegenerative Disorders and trauma survivors of all ages. Bree is an accomplished public speaker on topics of music therapy, intergenerational connection, trauma-informed care and business coaching.Creative Arts Therapies of the Palm Beaches Website.Also, find them on Facebook!NPR Interview with Parkland Survivors, "To Cope With Shooting, Parkland Students Use Art, Music Therapy"Parkland Town Hallfrom CNNThe Body Keeps The Score by Bessel Van Der KolkHolistic PsychologistTara Brach Stay Tuned for Bree's Personal Website for Public Speaking!

This episode is to supplement my interview with Dr David Unwin and is just with me reviewing and discussing some areas in more detail that David and I ran out of time to cover, including: Pathophysiology of DMT2 and different dietary considerations Environmental and farming practices Ending the Diet Wars Some further reading for those that want it: Environmental considerations: https://www.lifestylemedicine.org.au/content/is-the-path-to-health-the-same-path-to-environmental-sustainability/ Nutrition: Principles Before Position Part 3: The externalities of our food choices https://thegpshow.com/musings/pntpart3/  University of Oxford Grazed and Confused report: https://www.oxfordmartin.ox.ac.uk/downloads/reports/fcrn_gnc_report.pdf  UK Sustainable Food Trust: https://sustainablefoodtrust.org/articles/grazed-and-confused-an-initial-response-from-the-sustainable-food-trust/ EAT Lancet: https://eatforum.org/ and https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(20)30055-3/fulltext  2019 Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report from the American Diabetes Association https://care.diabetesjournals.org/content/diacare/early/2019/04/10/dci19-0014.full.pdf Diabetes Australia position statement on low carb approaches https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/dbd70857-a834-45b0-b6f1-ea2582bbe5c7.pdf Metabolic ward studies/randomised controlled feeding studies on various dietary composition: https://www.ncbi.nlm.nih.gov/pubmed/29844096 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951141/ Other paper on dietary composition: https://jim.bmj.com/content/65/8/1102 Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes https://diabetes.diabetesjournals.org/content/53/suppl_3/S16 Combination of saturated fats with high GI carbs causing further disease that saturated fats alone in "Saturated fat, carbohydrates and cardiovascular disease", 2011 https://www.ncbi.nlm.nih.gov/pubmed/21978979 Insulinogenic response of foods https://www.ncbi.nlm.nih.gov/pubmed/9356547 Personalized Nutrition by Prediction of Glycemic Responses https://www.ncbi.nlm.nih.gov/pubmed/26590418 Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis (observational) https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(18)30135-X/fulltext High/low animal protein diets and CVD: https://www.ncbi.nlm.nih.gov/pubmed/11108325 Dr Ornish Lifestyle Heart Disease Reversal study https://www.ncbi.nlm.nih.gov/pubmed/9863851 Other potentials for low carb approaches: The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders, 2019, Professor Sarnyai et al  https://www.ncbi.nlm.nih.gov/pubmed/31493223 Adherence to diets:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302176/ https://pubmed.ncbi.nlm.nih.gov/29522789/  https://www.mdpi.com/2072-6643/12/5/1251    Enjoy friends  

In medicine, a biomarker is anything used to determine the presence or development of a particular disease or biological state. They can be used to determine if an injury or disease has occurred, or even if a therapy is working. In this episode, Dr. Kendall Van Keuren-Jensen, a Professor in TGen Neurogenomics Division and Co-Director of TGen’s Center for Noninvasive Diagnostics, discusses how her team is working on ways to use biomarkers — in this case the molecular readout of RNA — as a non-invasive method for studying and treating complex diseases, such as those that affect the nervous system.

Why You Should Listen: In this episode, you will learn about autoimmunity and neurology in the context of Lyme disease and co-infections. About My Guest: My guest for this episode is Dr. Elena Frid, MD. Dr. Elena Frid is a Board Certified Neurologist and Clinical Neurophysiologist, widely regarded as a investigating diagnostician, adviser and treatment strategist specializing in Infection-Induced Autoimmune Disorders. Pioneering the field of Autoimmune Neurology, she often sees patients with complex cases of Lyme disease and co-infections resulting in multiple neurological complaints. Using cutting edge diagnostic tools and clinical expertise she is able to differentiate between idiopathic vs organic causes of various neurological disorders. Dr. Frid attended a coveted BA/MD program at Robert Wood Johnson Medical School and went on to North Shore-LIJ Health Care Systems where she completed residency in Neurology and fellowship in Clinical Neurophysiology (EMG / EEG). Her many areas of expertise are: General Neurology, Headaches & Migraines, Autoimmune Neurology, Neuropsychiatric and Neurodegenerative Disorders. Her knowledge has been sought by patients from all over the United States, as well as England, Germany, Spain, Australia, and Canada. She is one of the most experienced and unique Lyme doctors in the field, due to her background in Autoimmune Neurology, with heavy focus on diagnostic methodology, clinical expertise in neurology and psychiatry, and treatment therapy encompassing western and eastern medicine. Dr. Frid is a member of the American Academy of Neurology (AAN). She is a voting member of the International Lyme and Associated Diseases Society (ILADS), Medical Adviser to the Project Lyme organization, and member of the Independent Physicians of New York (IDNY). Upon request from families, Dr. Frid frequently collaborates on complex pediatric cases of Neuro Lyme disease with Dr. Charles Ray Jones, a world leading pediatric Lyme disease specialist with over 40 years’ experience in dealing with children with Lyme disease and other tick-borne illnesses. Key Takeaways: - How often is chronic Lyme neuro-Lyme? - What triggers autoimmunity? - Can autoimmune lab indicators be reversed? - What drives Hashimoto's? - How do you calm an over-active immune system? - What are the underlying issues in Chronic Fatigue, Fibromyalgia, MS, Parkinson's, ALS, and Alzheimer's? - What is PANDAS and PANS and does it resolve with treatment? - How do we keep our brains working well? - How can we heal the nerves after years of assault from chronic infections? - How can we reduce inflammation? - What causes seizures? Tinnitus? - What can we do about fear and anxiety involved in dealing with Lyme? Connect With My Guest: http://www.elenafridmd.com Interview Date: July 7, 2017 Disclaimer: The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.

Bloomberg Markets with Carol Massar and Cory Johnson. GUEST: Dr. Christopher Missling CEO Anavex Discussing current state of research into neurodegenerative disorders, such as Alzheimer's disease and Parkinson's, and Anavex's approach with ANAVEX 2-73. Caroline Hyde of Bloomberg Television also participates in the conversation. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

In this episode, our guest Kimberly Washington of the St. Jude's Project at Catholic Charities in Washington, D.C. discusses her "Therapeutic Patient Navigation" community-based project. She describes how this evidence-based intervention was developed to fill the gaps in services that support patients with Parkinson's, Huntington's, and Alzheimer's diseases.

Bloomberg Markets with Carol Massar and Cory Johnson. GUEST: Dr. Christopher Missling CEO Anavex Discussing current state of research into neurodegenerative disorders, such as Alzheimer's disease and Parkinson’s, and Anavex’s approach with ANAVEX 2-73. Caroline Hyde of Bloomberg Television also participates in the conversation.

With our aging population the incidence of brain disorders such as Alzheimer's disease are predicted to reach epidemic proportions. Look at AD and other neurodegenerative disorders. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 30142]

With our aging population the incidence of brain disorders such as Alzheimer's disease are predicted to reach epidemic proportions. Look at AD and other neurodegenerative disorders. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 30142]

With our aging population the incidence of brain disorders such as Alzheimer’s disease are predicted to reach epidemic proportions. Look at AD and other neurodegenerative disorders. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 30142]

With our aging population the incidence of brain disorders such as Alzheimer’s disease are predicted to reach epidemic proportions. Look at AD and other neurodegenerative disorders. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 30142]

Dana Laake and her special guest Valerie Estess will discuss Project A.L.S. and research against neurodegenerative disorders. Valerie Estess, along with her sisters Jenifer and Meredith, founded Project A.L.S., which has revolutionized the way that science and medicine approach disease research. As Director of Research, Valerie motivates world leading scientists and clinicians to work aggressively, openly, and together toward a deeper understanding of ALS, and closely related Alzheimer’s, Parkinson’s, and spinal cord injuries. In 6 years, Project A.L.S. has raised over $23 million for research. With her sister Jenifer, Valerie Estess authored the national bestseller Tales from the Bed. Jenifer Estess, a New York theater and film producer, was diagnosed with ALS (Lou Gehrig's disease) and passed away in 2003.

http://www.einstein.yu.edu - Joe Verghese, M.B.B.S, M.S, discusses the complex connections between frailty, mobility and cognitive decline in older adults and research to identify, prevent and treat frailty. Dr. Verghese is Chief of Geriatrics at Albert Einstein College of Medicine and Montefiore Medical Center and a professor of neurology and of medicine at Einstein. This edition of Einstein On, a research and medicine podcast, is hosted by Paul Moniz, managing director of communications and marketing at Einstein.

Robert Baloh, Washington University School of Medicine, St. Louis, MO, USA speaks on "Deciphering the role of TDP-43 in ALS and other neurodegenerative disorders". This seminar has been recorded by ICGEB Trieste

Minds Behind the MIND Lecture from 18 November 2010.

Our ageing society is confronted with a dramatic increase in patients suffering from tauopathies such as Alzheimer's disease, frontotemporal dementia and others. Typical neuropathological lesions including tangles composed of hyper-phosphorylated tau protein as well as severe neuronal cell death characterize these disorders. No mechanism-based cures are available at present. Genetically modified animals are invaluable models to understand the molecular disease mechanisms and to screen for modifying compounds. We recently introduced tau-transgenic zebrafish as a novel model for tauopathies. Our model allows recapitulating key pathological features of tauopathies within an extremely short time. Moreover, life imaging of tau-dependent neuronal cell death was performed for the very first time. This demonstrated tau-dependent neuronal cell loss independent of tangle formation. Finally, we exemplified that the zebrafish frontotemporal dementia model can be used to screen for drugs that prevent abnormal tau phosphorylation and neuronal cell death. Copyright (C) 2010 S. Karger AG, Basel

Matthew During, author of a phase I study of gene therapy in the treatment of Parkinson's disease dicusses the study, designed to assess safety and tolerability, shows encouraging early results for the treatment of Parkinson's disease and other neurodegenerative disorders.